Conjugated Monoclonal Antibodies Global Market To Reach Value Of About $11 Billion In 2025

2 Dec, 2021

Check out TBRC’s sale today for

The conjugated monoclonal antibodies market consists of the sales of conjugated monoclonal antibodies. Conjugated monoclonal antibodies are monoclonal antibodies (MAbs) associated with a chemotherapy drug or a radioactive particle. These are used in the treatment of cancer as they deliver the toxic substance directly to the tumor cells by reducing damage to normal cells in other parts of the body.

Global Conjugated Monoclonal Antibodies Market Size And Drivers:

The global conjugated monoclonal antibodies market is expected to grow from $7.98 billion in 2020 to $8.55 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The conjugated monoclonal antibodies market is expected to reach $11.43 billion in 2025 at a CAGR of 8%. The increasing popularity and therapeutic potential of conjugated monoclonal antibodies especially antibody-drug conjugate is expected to drive the conjugated monoclonal antibodies market over the forecast period.

Request For A Sample For The Global Conjugated Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3424&type=smp

Trends In The Global Conjugated Monoclonal Antibodies Market

Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships for developing new conjugated monoclonal antibodies shaping the market. For instance, in October 2019 NovoCodex, a subsidiary of Zhejiang Medicine Co Ltd collaborated for the second time with Ambrx Inc, a USA-based company engaged in developing protein therapeutics to develop and commercialize Ambrx's internally developed site-specific antibody-drug conjugate, ARX305 used for the treatment of CD70 positive cancers. Following the trend, in June 2020, Monopar Therapeutics, a USA-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered in collaboration to couple Monopar’s MNPR-101 a humanized urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage to a therapeutic radioisotope of NorthStar to create a highly selective agent, which has the potential to kill aberrantly activated cytokine-producing immune cells.

Global Conjugated Monoclonal Antibodies Market Segments:
The global conjugated monoclonal antibodies market is further segmented –
By Drugs: Adcetris, Kadcyla
By Technology: Cleavable Linker, Non-cleavable Linker
By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others
By Geography: The global conjugated monoclonal antibodies market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Conjugated Monoclonal Antibodies Market At:

https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

Conjugated Monoclonal Antibodies Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides conjugated monoclonal antibodies market overviews, analyzes and forecasts market size and growth for the global conjugated monoclonal antibodies market, conjugated monoclonal antibodies market share, conjugated monoclonal antibodies market players, conjugated monoclonal antibodies market segments and geographies, conjugated monoclonal antibodies market’s leading competitors’ revenues, profiles and market shares. The conjugated monoclonal antibodies market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)